company background image
KARO logo

Karo Pharma OM:KARO Stock Report

Last Price

kr60.70

Market Cap

kr16.6b

7D

0.5%

1Y

4.8%

Updated

25 Nov, 2022

Data

Company Financials

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

KARO Stock Overview

Karo Pharma AB (publ) develops and markets prescription drugs and over-the-counter products for pharmacies and retail sector in Sweden, Norway, Denmark, Finland, France, Germany, Italy, rest of Europe, the United States, and internationally.

KARO fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health1/6
Dividends0/6

Karo Pharma AB (publ) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Karo Pharma
Historical stock prices
Current Share Pricekr60.70
52 Week Highkr62.40
52 Week Lowkr49.25
Beta0.10
1 Month Change0.50%
3 Month Change1.17%
1 Year Change4.84%
3 Year Change56.85%
5 Year Change57.66%
Change since IPO-97.64%

Recent News & Updates

Recent updates

Karo Pharma (STO:KARO) Has No Shortage Of Debt

Oct 14
Karo Pharma (STO:KARO) Has No Shortage Of Debt

Is Karo Pharma (STO:KARO) A Risky Investment?

Jul 10
Is Karo Pharma (STO:KARO) A Risky Investment?

Karo Pharma (STO:KARO) Seems To Be Using A Lot Of Debt

Mar 23
Karo Pharma (STO:KARO) Seems To Be Using A Lot Of Debt

Karo Pharma's (STO:KARO) Strong Earnings Are Of Good Quality

Feb 24
Karo Pharma's (STO:KARO) Strong Earnings Are Of Good Quality

Is Karo Pharma AB (publ)'s (STO:KARO) 1.5% ROE Worse Than Average?

Feb 22
Is Karo Pharma AB (publ)'s (STO:KARO) 1.5% ROE Worse Than Average?

Did You Participate In Any Of Karo Pharma's (STO:KARO) Fantastic 144% Return ?

Feb 01
Did You Participate In Any Of Karo Pharma's (STO:KARO) Fantastic 144% Return ?

Shareholder Returns

KAROSE PharmaceuticalsSE Market
7D0.5%3.0%1.9%
1Y4.8%81.6%17.1%

Return vs Industry: KARO exceeded the Swedish Pharmaceuticals industry which returned -23.2% over the past year.

Return vs Market: KARO exceeded the Swedish Market which returned -24.8% over the past year.

Price Volatility

Is KARO's price volatile compared to industry and market?
KARO volatility
KARO Average Weekly Movement0.4%
Pharmaceuticals Industry Average Movement6.6%
Market Average Movement6.1%
10% most volatile stocks in SE Market12.9%
10% least volatile stocks in SE Market3.4%

Stable Share Price: KARO has not had significant price volatility in the past 3 months.

Volatility Over Time: KARO's weekly volatility (0%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1987225Christoffer Lorenzenhttps://www.karopharma.com

Karo Pharma AB (publ) develops and markets prescription drugs and over-the-counter products for pharmacies and retail sector in Sweden, Norway, Denmark, Finland, France, Germany, Italy, rest of Europe, the United States, and internationally. It offers skin health products under the Remescar, Locobase, Decubal, and indy beauty brand names; intimate health products under the Pevaryl, Multi Gyn, Asan, and Selexid brand names; and foot health products under the Pevaryl, CCS, Nailner, and wortie brands. The company also provides pain, cough, and cold products under the Paracet, Ibux, Mollipect, and Viruseptin brand names; prescription drugs under the Burinex, Centyl, Kaleorid, and Lithionit brands; and wellness products under the nutravita, Alpha Foods, Flux, Allévo, Dosett, Dax, and Lactocare brands.

Karo Pharma AB (publ) Fundamentals Summary

How do Karo Pharma's earnings and revenue compare to its market cap?
KARO fundamental statistics
Market capkr16.59b
Earnings (TTM)-kr189.85m
Revenue (TTM)kr3.47b

4.8x

P/S Ratio

-87.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
KARO income statement (TTM)
Revenuekr3.47b
Cost of Revenuekr1.50b
Gross Profitkr1.96b
Other Expenseskr2.15b
Earnings-kr189.85m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.69
Gross Margin56.67%
Net Profit Margin-5.48%
Debt/Equity Ratio104.8%

How did KARO perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.